Close

Shuwen Biotech Receives CE Mark for EGFR Mutation PCR Kit for Lung Cancer

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

Shuwen Biotech announced that it has received CE-IVD marking for its EGFR real time PCR detection kit allowing the company to market its kit in countries that recognize the designation.

The CE Marked kit showcases Shuwen’s strengthening research and development capabilities which ultimately have led to a series of increasingly innovative products for the market. The EGFR kit has a limit of mutation detection at 0.1% in a background of wild-type DNA for key mutations. The kit contains lyophilized reagents which withstand at least 12 freeze/thaw cycles, increasing the kit’s stability while lowering logistics costs for clients.

In addition to the EGFR real time PCR detection kit, Shuwen is leveraging its proprietary CODAR-PCR technology on real-time PCR platform to finalize development of a number of other innovative diagnostics such as EGFR-T790M (liquid biopsy), BRAF, ALK, and ROS1 mutation detection assays. Initial tests show that the EGFR-T790M mutation detection assay has a limit of mutation detection at an exceptional 0.01% in a background of wild-type DNA which holds significant value to various clinical and drug development strategies worldwide.

“At Shuwen, we believe innovation is fundamental to leading the market into new frontiers and this is what we primarily focus on,” said Jay Z. Zhang, CEO of Shuwen Biotech. “Through cutting-edge technical innovations we aim to raise the bar with regards to sensitivity, specificity, convenience of use and transport in molecular diagnostic kits.”

About Shuwen Biotech
Led by U.S. and European diagnostic industry veterans, Shuwen Biotech is engaged in licensing, developing, marketing and distributing innovative products and services for disease diagnosis and personalized medicine. The company strives to provide doctors and their patients with a comprehensive menu of the most innovative products and services for improved disease prediction, screening, diagnosis, prognosis and treatment in the areas of cancer, maternal fetal medicine, acute care, and preventive testing.

Contact
Dr. Vafa Amirkia
bd@shuwendx.cn

Latest stories